Peapod Lane Capital LLC Makes New $2.02 Million Investment in Fulgent Genetics, Inc. (NASDAQ:FLGT)

Peapod Lane Capital LLC purchased a new position in shares of Fulgent Genetics, Inc. (NASDAQ:FLGT - Free Report) during the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor purchased 109,459 shares of the company's stock, valued at approximately $2,022,000. Fulgent Genetics makes up approximately 2.0% of Peapod Lane Capital LLC's holdings, making the stock its 18th largest position. Peapod Lane Capital LLC owned 0.36% of Fulgent Genetics at the end of the most recent quarter.

A number of other hedge funds have also recently added to or reduced their stakes in FLGT. GAMMA Investing LLC lifted its position in shares of Fulgent Genetics by 45.5% during the fourth quarter. GAMMA Investing LLC now owns 2,133 shares of the company's stock worth $39,000 after purchasing an additional 667 shares in the last quarter. Point72 DIFC Ltd bought a new position in Fulgent Genetics in the 3rd quarter worth approximately $46,000. R Squared Ltd acquired a new position in Fulgent Genetics during the 4th quarter worth $74,000. Gladius Capital Management LP bought a new position in Fulgent Genetics in the 3rd quarter valued at $81,000. Finally, Easterly Investment Partners LLC acquired a new stake in shares of Fulgent Genetics in the 3rd quarter valued at $208,000. Institutional investors own 48.06% of the company's stock.

Insider Activity

In other news, CEO Ming Hsieh sold 2,227 shares of the business's stock in a transaction dated Monday, November 25th. The stock was sold at an average price of $18.26, for a total transaction of $40,665.02. Following the completion of the transaction, the chief executive officer now directly owns 703,711 shares in the company, valued at approximately $12,849,762.86. The trade was a 0.32 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders have sold a total of 3,413 shares of company stock valued at $62,321 in the last 90 days. 31.76% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

Several equities analysts have recently issued reports on the company. Piper Sandler cut their price target on Fulgent Genetics from $26.00 to $22.00 and set a "neutral" rating on the stock in a research note on Monday, November 11th. StockNews.com downgraded shares of Fulgent Genetics from a "hold" rating to a "sell" rating in a research report on Wednesday, November 27th.

Fulgent Genetics Stock Up 0.2 %

FLGT stock traded up $0.04 during midday trading on Monday, reaching $16.90. The company's stock had a trading volume of 174,996 shares, compared to its average volume of 235,580. The business's 50-day simple moving average is $17.94 and its 200-day simple moving average is $19.96. The stock has a market cap of $516.97 million, a PE ratio of -3.06 and a beta of 1.39. Fulgent Genetics, Inc. has a 52 week low of $15.99 and a 52 week high of $26.36.

Fulgent Genetics Company Profile

Fulgent Genetics, Inc, together with its subsidiaries, provides clinical diagnostic and therapeutic development solutions to physicians and patients in the United States and internationally. The company's clinical diagnostic solutions include molecular diagnostic testing; genetic testing; anatomic pathology laboratory tests and testing services, such as gastrointestinal pathology, dermatopathology, urologic pathology, breast pathology, neuropathology, and hematopathology; oncology tests and testing services; and sequencer services related to hereditary cancer, reproductive health, and other diseases.